Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “SNNA.”

Based in Westlake Village, California, Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of targeted, topical products in medical dermatology and aesthetics.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Josephine Chen. The tax team included partner Rachel D. Kleinberg and associate Joseph M. Gerstel. The intellectual property and technology team included associate Yifu Chen. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post